Trends in Financial Relationships Between Industry and Radiation Oncologists Versus Other Physicians in the United States from 2014 to 2018.
Trends in Financial Relationships Between Industry and Radiation Oncologists Versus Other Physicians in the United States from 2014 to 2018.
复制标题
DOI：
10.1016/j.ijrobp.2020.08.043
复制
发表时间：
2021-01-01
期刊：
影响因子：
--
通讯作者：
Chimonas S
中科院分区：
文献类型：
--
作者：
Marshall DC;Tarras ES;Rosenzweig K;Yom SS;Hattangadi-Gluth J;Murphy J;Korenstein D;Chimonas S
开放式支付（OP）透明度计划公布了行业医生支付的数据，部分原因是为了阻止被认为不合适的关系，包括礼物，餐费和发言人局费用。我们评估了医生级别的支付趋势，以测试OP的实施是否会减少行业-放射肿瘤学家（RO）的相互作用，或者与医学肿瘤学家（MO）和其他医院医生（HBP）相比，将相互作用转移到被认为更合适的地方。我们进行了一项回顾性的、基于人群的队列研究，比较了2014年美国RO与MO和HBPs的实践情况，并与2014-2018年的一般（非研究）支付相匹配。按付款性质分析和报告了付款趋势。确定了前10家公司向区域办事处支付的款项的价值。从2014年到2018年，3，379（90.3%）RO接受了106，930笔付款，总额为4080万美元。RO的每名医生的支付数量和价值低于MO，高于HBPs。RO接受支付的比例从2014年的61.8%上升到2018年的64.2%; MO接受支付的比例从78.7%下降到77.7%; HBP的比例分别从40.8%下降到37.5%。RO和MO接受的每名医生的年度价值和付款次数增加。在娱乐、膳食、旅行/住宿和礼品方面，RO的支付有所增加，而MO和HBPs则保持稳定或下降。所有群体的咨询费都有所增加。顶级RO支付者生产新型癌症治疗药物、水凝胶垫片、放射治疗机和阿片类药物。自OP成立以来，行业向RO付款变得越来越普遍，而对MO和HBP的付款则越来越少。向区域办事处和管理组织支付的款项越来越频繁，与其他支付额正在下降的沉重负担者相比，支付额略有增加。在RO中没有看到关系性质的大的变化。在区域办事处，需要更多地处理财务利益冲突问题。
The Open Payments (OP) transparency program publishes data on industry-physician payments, in part to discourage relationships considered inappropriate including gifts, meals, and speaker’s bureau fees. We evaluated trends in physician-level payments to test whether implementation of OP resulted in fewer industry-radiation oncologist (RO) interactions or shifted interactions towards those considered more appropriate as compared to medical oncologists (MOs) and other hospital-based physicians (HBPs). We performed a retrospective, population-based cohort study of practicing US ROs versus MOs and HBPs in 2014 matched to general (non-research) payments between 2014–2018. Trends in payments were analyzed and reported by nature of payment. Values of payments to ROs from the top 10 companies were identified. From 2014–2018, 3,379 (90.3%) ROs accepted 106,930 payments totaling $40.8 million. The per-physician number and value of payments was lower in RO than MO, and higher than HBPs. The proportion of ROs accepting payments increased from 61.8% in 2014 to 64.2% in 2018; the proportion of MOs accepting payments decreased from 78.7% to 77.7%; the proportion of HBPs decreased from 40.8% to 37.5%, respectively. The annual per-physician value and number of payments accepted by RO and MO increased. Payments in entertainment, meals, travel/lodging and gifts increased among ROs and remained stable or decreased among MOs and HBPs. Consulting payments increased across all groups. Top RO payors produced novel cancer therapeutics, hydrogel spacers, radiation treatment machines, and opioids. Industry payments to ROs have become more common since OP’s inception, while becoming less common for MOs and HBPs. Payments to ROs and MOs have become more frequent and of modestly increasing value, compared to other HBPs for whom the value is decreasing. No large changes in the nature of relationships were seen in ROs. Increased engagement with financial conflicts of interest is needed in RO.
登录
查看更多内容
影响因子：
8.9
作者：
Marshall, Deborah C.;Jackson, Madeleine E.;Hattangadi-Gluth, Jona A.
通讯作者：
Hattangadi-Gluth, Jona A.
影响因子：
28.4
作者：
Mitchell, Aaron P.;Basch, Ethan M.;Dusetzina, Stacie B.
通讯作者：
Dusetzina, Stacie B.
影响因子：
120.7
作者：
Ledley, Fred D.;McCoy, Sarah Shonka;Cleary, Ekaterina Galkina
通讯作者：
Cleary, Ekaterina Galkina
影响因子：
39
作者：
Hadland SE;Cerdá M;Li Y;Krieger MS;Marshall BDL
通讯作者：
Marshall BDL
DOI：
10.1016/j.ijrobp.2015.09.004
发表时间：
2016-01-01
影响因子：
7
作者：
Jairam, Vikram;Yu, James B.
通讯作者：
Yu, James B.